NCT03064269

CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · Industry
• Sex: All
• Age: 10 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.

Detailed description

CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells

Conditions

• B-cell Acute Lymphocytic Leukemia

Interventions

Type	Name	Description
BIOLOGICAL	CD19 CAR-T cells	CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells

Timeline

• Start date: 2017-03-01
• Primary completion: 2024-12-31
• Completion: 2025-12-31
• First posted: 2017-02-27
• Last updated: 2023-11-29

Locations

1 site across 1 country: China